Christina M. Schueller

Christina M. Schueller

Auto-generated profile, based on publicly available information

Christina M. Schueller

Department of Laboratory Medicine Medical University of Vienna Vienna Austria

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
BSBenjamin Salzer
Benjamin Salzer
CSChristina M. Schueller
Christina M. Schueller
CZCharlotte U. Zajc
Charlotte U. Zajc
TPTimo Peters
Timo Peters
MSMichael A. Schoeber
Michael A. Schoeber
MLManfred Lehner
Manfred Lehner
T cells engineered to express chimeric antigen receptors (CAR-T cells) have shown impressive clinical efficacy in the treatment of B cell malignancies. However, the development of CAR-T cell therapies for solid tumors is hampered by the lack of truly tumor-specific antigens and poor control over T cell activity. Here we present an avidity-controlled CAR (AvidCAR) platform with inducible and logic control functions. The key is the combination of (i) an improved CAR design which enables controlled CAR dimerization and (ii) a significant reduction of antigen-binding affinities to introduce dependence on bivalent interaction, i.e. avidity. The potential and versatility of the AvidCAR platform is exemplified by designing ON-switch CARs, which can be regulated with a clinically applied drug, and AND-gate CARs specifically recognizing combinations of two antigens. Thus, we expect that AvidCARs will be a highly valuable platform for the development of controllable CAR therapies with improved tumor specificity.

24 March 2021 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
SASarada Achyutuni
Sarada Achyutuni
HNHarini Nivarthi
Harini Nivarthi
AMAndrea Majoros
Andrea Majoros
EHEva Hug
Eva Hug
CSChristina Schueller
Christina Schueller
RKRobert Kralovics
Robert Kralovics
Myeloproliferative neoplasms (MPNs) are characterized by a pathologic expansion of myeloid lineages. Mutations in JAK2, CALR and MPL genes are known to be three prominent MPN disease drivers. Mutant CALR (mutCALR) is an oncoprotein that interacts with and activates the thrombopoietin receptor (MPL) and represents an attractive target for targeted therapy of CALR mutated MPN. We generated a transgenic murine model with conditional expression of the human mutant exon 9 (del52) from the murine endogenous Calr locus. These mice develop essential thrombocythemia like phenotype with marked thrombocytosis and megakaryocytosis. The disease exacerbates with age showing prominent signs of splenomegaly and anemia. The disease is transplantable and mutCALR stem cells show proliferative advantage when compared to wild type stem cells. Transcriptome profiling of hematopoietic stem cells revealed oncogenic and inflammatory gene expression signatures. To demonstrate the applicability of the transgenic animals for immunotherapy, we treated mice with monoclonal antibody raised against the human mutCALR. The antibody treatment lowered platelet and stem cell counts in mutant mice. Secretion of mutCALR did not constitute a significant antibody sink. This animal model not only recapitulates human MPN but also serves as a relevant model for testing immunotherapeutic strategies targeting epitopes of the human mutCALR.

30 August 2022 in American Journal of Hematology
Verified
Journal Article
Closed access
CSChristina M. Schueller
Christina M. Schueller
AMAndrea Majoros
Andrea Majoros
HNHarini Nivarthi
Harini Nivarthi
RKRobert Kralovics
Robert Kralovics